Medicines

  1. Why is niraparib (Zejula) important for women with recurrent ovarian cancer?

    The European Medicines Agency has recently approved Niraparib (Zejula) for use in the European Union as a treatment for women struggling with a specific type of advanced ovarian cancer known as high-grade serous epithelial ovarian cancer, which includes cancers that affect the peritoneum and/or the fallopian tubes.

    smiling woman with friends 

    Read more »
  2. What’s the difference between a brand name and a generic medicine?

    brand name generic medicine
    When a new medicine gets approved for use and for sale in a specific region, it’s usually given a brand name by the pharmaceutical company who discovered or developed it.

    Read more »
  3. Preapproval vs unapproved or elsewhere approved medicines

    ‘Unapproved medicines’, ‘compassionate use’, ‘early access drugs’..

    preapproval vs unapproved

    Read more »
  4. New prices negotiated! Reductions for 38 products

    Price decreases for 38 medicines

    Read more »
  5. What are the latest breakthroughs in multiple sclerosis (MS)?

    The potential of neuroprotective agents for a whole new form of treatment.

    MS

    Read more »
  6. New medicines coming soon!

    A list of medicines TheSocialMedwork will soon be making available.

    New medicines

    Read more »
  7. Promising Developments in Treatment of Multiple Myeloma!

    Darzalex (daratumumab) combination under review as first-line option.

    Multiple Myeloma

    Read more »
  8. Spinraza, the new medicine for spinal muscular atrophy

    Is there substance to the claims that it's a groundbreaking treatment?

    Spinraza

    Read more »
  9. Why is there often a substantial delay in getting access to new medicines – even after they are approved?

    We talk to Sera, our Medicines Sourcing Manager about why drug delays happen...

    Drug delays

    Read more »
  10. A new medicine for Alzheimer's disease?

    Introducing a breakthrough known as 'CT1812'

    alzheimer disease

    Read more »
Posts loader

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.